Simpson Thacher is representing Blackstone in connection with its sale of Alinamin Pharmaceutical Co., Ltd. (“Alinamin”) to MBK Partners. Blackstone will re-invest a minority stake in Alinamin upon closing of the sale. Terms of the transaction were not otherwise disclosed.~~Alinamin is a leading consumer healthcare company in Japan focusing on supplements and nonprescription drugs. The Firm also represented Blackstone on its acquisition of Alinamin in 2021 from Takeda Pharmaceutical.~~The Simpson Thacher team includes Anthony King, Sonya Ho, Paul Kim and Tiffany Shih (M&A); Étienne Renaudeau, Sarah Chaudhuri and Luke Cowdell (Antitrust); Makiko Harunari and Chenyu Cui (Banking & Credit); Meredith Jones and Paul Jansch (Tax); Ron Ben-Yehuda (Intellectual Property); Steven Klar and Richard Zhang (Funds); and Gregory Grogan and Pasco Struhs (ECEB).